ORCHARD THERAPEUTICS PLC-ADR(NASDAQ:ORTX) stock News

ORTX Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

2 years ago - By: Benzinga

Orchard Therapeutics: Q3 Earnings Insights

2 years ago - By: Investor's Business Daily - Mentions: SRPT HCM

Sarepta Therapeutics Stock Showing Rising Relative Strength

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

a year ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

2 years ago - By: Orchard Therapeutics (Europe) Limited

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

2 years ago - By: Orchard Therapeutics (Europe) Limited

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

2 years ago - By: Seeking Alpha

Orchard Therapeutics gains FDA fast track status for Hurler syndrome therapy (NASDAQ:ORTX)

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

2 years ago - By: Kahn Swick & Foti, LLC

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

2 years ago - By: Seeking Alpha

Orchard says no FDA AdCom on gene therapy (NASDAQ:ORTX)

2 years ago - By: Seeking Alpha

Orchard Therapeutics GAAP EPS of -$0.15 beats by $0.30, revenue of $6.3M misses by $1.6M (NASDAQ:ORTX)

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

2 years ago - By: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

2 years ago - By: Kahn Swick & Foti, LLC

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

2 years ago - By: Benzinga - Mentions: CAG SP LW CMBM ...

ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock News

ORTX Latest News, Press Relases and Analysis

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Orchard Therapeutics: Q3 Earnings Insights

Sarepta Therapeutics Stock Showing Rising Relative Strength

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

Orchard Therapeutics gains FDA fast track status for Hurler syndrome therapy (NASDAQ:ORTX)

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

Orchard says no FDA AdCom on gene therapy (NASDAQ:ORTX)

Orchard Therapeutics GAAP EPS of -$0.15 beats by $0.30, revenue of $6.3M misses by $1.6M (NASDAQ:ORTX)

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

Crude Oil Down 2%; ConAgra Brands Earnings Top Views